Home Newsfeeds Morgan Stanley Maintains Equal-Weight on Embecta, Lowers Price Target to $31

Morgan Stanley Maintains Equal-Weight on Embecta, Lowers Price Target to $31

Morgan Stanley analyst Cecilia Furlong maintains Embecta (NASDAQ:EMBC) with a Equal-Weight and lowers the price target from $33 to $31.

byBenzinga Newsdesk

December 21, 2022

1 minute read

Morgan Stanley analyst Cecilia Furlong maintains Embecta (NASDAQ:EMBC) with a Equal-Weight and lowers the price target from $33 to $31.

French Petrol Stations Strike Continues As Union Rejects Wage Talk ‘Blackmail’

By Vandana Singh

October 10, 3:17 PM

Workers striking at TotalEnergies SE (NYSE:TTE) and Exxon Mobil Corp’s (NYSE:XOM) French refineries have rejected a pay offer, extending the strike that…

TTE

Nvidia, Toyota, READY Robotics Partner To Launch Sim-to-Real Robotic Programming In Industrial Manufacturing

By Nabaparna Bhattacharya

January 17, 2:51 PM

NVIDIA, Toyota, and READY Robotics revolutionize industrial robotics with Sim-to-Real programming. The collaboration leverages NVIDIA Isaac Sim and READY ForgeOS to enhance safety and efficiency in Toyota's manufacturing.

NVDA

Bristol Myers’ Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients

By Vandana Singh

January 29, 8:43 AM

Results from Bristol Myers Squibb's Phase 3 CheckMate -67T trial on subcutaneous Opdivo (nivolumab) for advanced clear cell renal cell carcinoma. Noninferiority compared to IV Opdivo.

BMY